更新于：2024-11-01

Neck Pain

颈部疼痛

更新于：2024-11-01

基本信息

别名

Ache, Neck、Aches, Neck、Anterior Cervical Pain

+ [76]

简介

Discomfort or more intense forms of pain that are localized to the cervical region. This term generally refers to pain in the posterior or lateral regions of the neck.

关联

项与颈部疼痛相关的药物

Analgecine

痘苗病毒致炎兔皮提取物

靶点

5-HT receptor x bradykinin receptor

作用机制

5-HT receptor调节剂 [+1]

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2003-12-09

Lidocaine

利多卡因

靶点

SCNA

作用机制

SCNA阻滞剂

在研机构

北京泰德制药股份有限公司 [+14]

原研机构-

在研适应症

疱疹后神经痛 [+13]

非在研适应症

慢性疼痛 [+2]

最高研发阶段批准上市

首次获批国家/地区-

首次获批日期1947-01-01

Caffeine/Ibuprofen

咖啡因/布洛芬

靶点

A1R x A2aR x COX

作用机制

A1R拮抗剂 [+2]

在研机构

C.H. Boehringer Sohn AG & Co. KG

原研机构

C.H. Boehringer Sohn AG & Co. KG

在研适应症

疼痛

非在研适应症

背痛 [+1]

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期1800-01-20

1,484

项与颈部疼痛相关的临床试验

IRCT20191023045212N1 / SuspendedN/AIIT

Effect Of Sustained Natural Apophyseal Glide Versus Cervical Manipulation In Treatment Of Mechanical Neck Pain

开始日期2640-10-11

申办/合作机构-

NCT02774694 / Not yet recruitingN/AIIT

Observational Study of the Nociceptive Flexion Reflex Threshold to Predict Outcome After Interventional Pain Management Procedures in Patients With Chronic Back and Neck Pain. A Study of Diagnostic Accuracy

Interventional pain management for back and neck pain is widely used, but the indications and relative merits of these techniques rest subject to discussion. This study aims to identify prognostic criteria for patients who might specifically benefit from interventional pain management. Specifically, the nociceptive reflex threshold will be investigated, which is a measure of central sensibilisation and thus a potentially important prognostic factor.

开始日期2026-01-01

申办/合作机构

Les Hôpitaux Universitaires de Genève

NCT06640322 / Not yet recruitingN/AIIT

Turkish Validity and Reliability of the Craniocervical Dysfunction Index in Patients With Non-specific Neck Pain

The aims of this study were to perform cultural adaptation of the Craniocervical Dysfunction Index in patients with non-specific neck pain, reliability and validity of the index Turkish speaking adults.

开始日期2025-01-01

申办/合作机构-

100 项与颈部疼痛相关的临床结果

登录后查看更多信息

100 项与颈部疼痛相关的转化医学

登录后查看更多信息

0 项与颈部疼痛相关的专利（医药）

登录后查看更多信息

16,639

项与颈部疼痛相关的文献（医药）

2025-02-01·Neurology Clinical Practice

Results From the PRODROME Trial Screening Period

Article

作者: Schwedt, Todd J. ; Hussar, Cory ; Trugman, Joel M. ; Goadsby, Peter J. ; Lipton, Richard B. ; Yu, Sung Yun ; Liu, Chengcheng ; Finnegan, Michelle ; Klein, Brad C. ; Chiang, Chia-Chun

Background and ObjectiveLimited data are available describing the frequency, severity, and consistency of prodromal symptoms followed by headache. This analysis of the PRODROME trial screening period characterized prodromal symptoms in people with migraine, including the most common symptoms and their severity, and the frequency and consistency with which prodromal symptoms were followed by headache.MethodsPRODROME was a multicenter, randomized, double-blind, placebo-controlled, crossover trial conducted in the United States that enrolled adults with 2-8 migraine attacks per month who stated they could identify prodromal symptoms that were reliably followed by a headache. The trial included a 60-day screening period designed to test the predictive validity of "qualifying prodrome events" before the onset of headache. Participants used an eDiary to report qualifying prodrome events, defined as prodromal symptoms whereby the participant was confident a headache would follow within 1-6 hours. This analysis evaluated common prodromal symptoms and their severity, time from prodrome onset to headache onset, and the percentage of participants who identified prodromal symptoms that were followed by a headache ≥75% of the time over the 60-day screening period.ResultsA total of 920 participants entered eDiary data, with a mean of 5.2 qualifying prodrome events during the 60-day screening period. A total of 4,802 qualifying prodrome events were recorded. The most common prodromal symptoms identified were sensitivity to light (57.2%; 2,748/4,802), fatigue (50.1%; 2,408/4,802), neck pain (41.9%; 2,013/4,802), sensitivity to sound (33.9%; 1,630/4,802), either difficulty thinking or concentrating (30.0%; 1,442/4,802), and dizziness (27.8%; 1,333/4,802). Of all qualifying prodrome events reported, 81.5% (3,913/4,802) were followed by headache of any intensity within 1-6 hours. For each participant, a mean of 84.4% of their qualifying prodrome events were followed by a headache within 1-6 hours, with 76.9% of participants identifying qualifying prodrome events that were followed by headache within 1-6 hours ≥75% of the time.DiscussionParticipants were able to identify migraine attacks in which prodromal symptoms were reliably followed by a headache within 1-6 hours. These findings suggest the potential for initiating treatment during the prodrome to prevent headache.Trial Registration InformationClinicalTrials.gov NCT04492020. Submitted: July 27, 2020; First patient enrolled: August 21, 2020. clinicaltrials.gov/study/NCT04492020.

2024-12-31·NMC Case Report Journal

Rapidly Progressing Intramedullary Spinal Cord Abscess: A Case Report

作者: Mishima, Kazuhiko ; Mizuno, Reina ; Shirahata, Mitsuaki ; Suzuki, Tomonari ; Homma, Taku ; Ehara, Takuro

Intramedullary spinal cord abscess is a rare and severe infectious disease characterized by devastating neurological deficits. We report a case of cervical intramedullary spinal cord abscess in a 74-year-old diabetic male with a 3-day history of neck pain and weakness in the right lower extremity. Magnetic resonance imaging revealed a ring-shaped contrast lesion in C3-C6 of the cervical spinal cord with extensive edema. Further, 1 day after admission, he became comatose (Glasgow Coma Scale E1VtM1), and a computed tomography head scan revealed hydrocephalus. Despite emergency ventricular drainage, the patient's level of consciousness remained unchanged. Magnetic resonance imaging performed 1 day after surgery revealed bilateral intracranial extension of the abscess into the thalamus and caudate nucleus. The patient died 19 days after admission. Our report is the first case of extensive brain abscess development over a short period. Based on our experience, prompt administration of antibiotics and emergency abscess drainage of the cervical cord (and ventricular drainage, if necessary) are recommended in cases of neurological deterioration in patients with cervical intramedullary spinal cord abscess.

2024-12-01·Journal of Vascular Surgery Cases, Innovations and Techniques

Pediatric carotid body tumors: A case report and systematic review

Article

作者: Al-Omran, Mohammed ; Bin Onayq, Abdulhakim Ibrahim ; Alanezi, Tariq

Carotid body tumors (CBTs), or chemodectomas, are rare, especially in the pediatric population. They often present with minimal symptoms, making timely diagnosis challenging. This case report and systematic review highlights a distinctive presentation and summarize the current evidence on pediatric CBTs. We report a case of a 13-year-old girl presenting with neck pain and a left-sided neck mass. After extensive evaluation, a Shamblin type III tumor was identified and removed surgically. Postoperatively, the patient experienced transient hypertension and significant dysphagia, both of which resolved within a few weeks with no permanent sequelae. Histology confirmed a benign paraganglioma. A systematic literature review of PubMed identified 29 cases from 23 published studies spanning from 1968 to 2024. The average age at diagnosis was 12.6 ± 3.6 years. The most common symptom was a neck mass or swelling, reported in 75% of cases (n = 21). Tumor sizes ranged from 1.3 to 8.0 cm, with Shamblin III being the most frequent classification. Gross total resection (n = 25 [89.3%]) alone or in combination with preoperative embolization (n = 10 [35.7%]) were the most common methods of management. In 62.1% of cases, there were no permanent complication or sequelae. The proximity to vital neurovascular structures and high vascularity in pediatric patients necessitates careful perioperative interdisciplinary management. Owing to their rarity and nonspecific presentation, CBTs often remain undiagnosed for years. They respond well to treatment, but can be fatal if untreated, underscoring the importance of including CBTs in the differential diagnosis of pediatric neck masses.

203

项与颈部疼痛相关的新闻（医药）

2024-10-23

·米内网

【聚焦】16亿中药大品种，最新国家药品标准曝光

精彩内容近日，国家药典委员会（ChPC）发布公示，拟修订小柴胡颗粒国家药品标准。小柴胡颗粒用于外感病、邪犯少阳证等，2023年在中国三大终端六大市场销售规模超过16亿元，同比增长20.69%。今年10月以来，ChPC至少公示了6款中成药的国家药品标准草案，均为OTC甲类品种（含双跨），独家品种占半数。来源：ChPC官网小柴胡颗粒主要由柴胡、黄芩、姜半夏、党参、生姜、甘草、大枣等组成，功能主治解表散热、疏肝和胃，用于外感病，邪犯少阳证，症见寒热往来、胸胁苦满、食欲不振、心烦喜呕、口苦咽干等。米内网数据显示，小柴胡颗粒为全国医保甲类药、OTC甲类品种，近年来该药在中国三大终端六大市场（统计范围详见本文末）销售额逐年攀升，2023年销售规模突破16亿元，同比增长20.69%；其中城市实体药店终端为主力销售战场，市场规模超过11亿元，是感冒中成药TOP2产品。近年来中国三大终端六大市场小柴胡颗粒销售趋势（单位：万元）来源：米内网格局数据库今年10月以来，ChPC至少公示了6款中成药的国家药品标准草案，其中独家品种（含剂型独家）占比达50%，包括马应龙药业的麝香痔疮栓、福瑞达医药的颈痛颗粒和香雪制药的橘红痰咳液；按治疗大类统计，呼吸系统疾病用药、骨骼肌肉系统疾病用药、消化系统疾病用药分别占3个、2个和1个席位。今年10月以来ChPC公示的国家药品标准中成药名单注：带*为独家品种来源：ChPC官网，米内网整理 6款拟公示的中成药中，有1款医保甲类药、3款医保乙类药和2款非医保药；从OTC分类看，均属于甲类品种，包括橘红痰咳液、麝香痔疮栓2款双跨品种。资料来源：米内网数据库、ChPC官网注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。数据统计截至10月22日，如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

专利侵权

2024-10-22

·PRNewswire

CENTER FOR PAIN MANAGEMENT WELCOMES DR. MICHAEL DORWART, MD.

INDIANAPOLIS, Oct. 22, 2024 /PRNewswire/ -- Center for Pain Management, together with American Pain Consortium, a leading network of interventional pain practices, is pleased to announce that Michael Dorwart, MD, has joined their practice and will be seeing patients starting October 23, 2024. Dr. Dorwart brings with him years of experience practicing Interventional Pain Medicine and a reputation for providing compassionate and comprehensive care. His experience and dedication to advancing the field of Interventional Pain Medicine will provide new opportunities for patients to access cutting-edge treatments and personalized care. As a center of excellence, the addition of Dr. Dorwart will further support their comprehensive intrathecal care services through his strong commitment to neuromodulation and extensive expertise in intrathecal pump management. He will be joining the Center for Pain Management to lead the newest, state-of-the-art facility in downtown Indianapolis, located in the OneAmerica Tower. Patients can expect a patient-centered approach that aligns with the Center for Pain Management's commitment to providing unparalleled medical care and concierge-level service. "We are excited to welcome Dr. Dorwart to join our practice," said CEO Edward Kowlowitz, MD. "Dr. Dorwart's experience in Interventional Pain Medicine and dedication to patient care will further enhance the unmatched level of service we provide to our patients. He will offer a unique combination of expert level care, a wide range of advanced treatments, along with a personalized and patient-centered approach, aligning with the Center for Pain Managements standard for providing next level care." In addition to a wealth of experience in patient care, he brings years of leadership experience having served as an Assistant Professor of Clinical Anesthesia for the Indiana University Pain Medicine Center. Beyond these achievements, Dr. Dorwart's dedication to advancing the field of Interventional Pain Medicine extends nationally. He has served on numerous Interventional Pain Medicine committees, having taught at the North American Neuromodulation Society & serving on the ASA MOCA Committee. Dr. Dorwart received his medical degree from the Indiana University School of Medicine located in Indianapolis, IN. He completed his residency through the Indiana University Department of Neurology and went on to complete his Pain Fellowship through Indiana University Department of Anesthesiology Pain Division. He holds dual board certification through the American Board of Psychiatry and Neurology as well as Pain Medicine and is a member of the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the North American Neuromodulation Society. Dr. Dorwart is now accepting new patients. To experience a level of personalized and comprehensive care unique to the Center for Pain Management, please schedule an appointment by visiting or call (317) 706-7246. Center for Pain Management, supported by American Pain Consortium, proudly serves Indiana with 9 clinics and 4 Ambulatory Surgery Centers statewide and has been treating a wide range of acute and chronic pain conditions since 1993. The physicians specialize in back pain, neck pain, headache, and joint pain resulting from injuries, arthritis, cancer, fibromyalgia, failed back surgery, Complex Regional Pain Syndromes (CRPS), and other disorders. Their team of Board Certified and licensed physicians, physician assistants, nurse practitioners, physical therapists, and psychologists work together to provide multidisciplinary pain treatment and management. Patients can find expert-level care serving the communities of Lafayette, Kokomo, Carmel, Indianapolis (North Meridian), Downtown Indianapolis, Avon, Greenwood, Jasper, & Evansville. To learn more, visit or call 317-706-7246. To learn more about American Pain Consortium, visit . SOURCE Center for Pain Management WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

高管变更

2024-10-22

·奇点网

在家就能“电走”抑郁！

*仅供医学专业人士阅读参考长久以来，抗抑郁药和心理治疗是抑郁症的标准治疗方法，但是仍有超过三分之一的患者对这些传统治疗反应不佳，无法获得完全缓解。近年来，针对这种治疗瓶颈，一种非侵入性脑刺激技术——经颅直流电刺激（tDCS）逐渐受到关注。tDCS通过向大脑皮层传递微弱电流，调节与情绪调控相关的脑区功能，显示出改善抑郁症状的潜力。由于其便携性和安全性，以及技术的进步和证据的成熟，科学家们尝试将tDCS推进到日常家庭环境中的使用，而无需抑郁症患者频繁前往医院进行治疗。今日，英国东伦敦大学Cynthia H. Y. Fu团队完成的2期临床试验结果发表于《自然·医学》杂志[1]。这项共涉及174名患者的随机对照试验完全远程进行，结果显示，对标准治疗耐药或未接受过标准治疗的中至重度抑郁症患者，在家自行采取tDCS治疗是可行的。在家庭环境下进行10个星期的治疗周期后，采用tDCS治疗的抑郁症患者症状改善幅度明显高于假治疗组，抑郁评分较基线平均减少9.41分，约45%的tDCS治疗组患者达到症状缓解，安全性可接受。美国得克萨斯大学的神经心理学家Shawn McClintock发表评论表示[2]，“当我们谈到心理健康治疗，可及性是绕不开的障碍。而这项试验，真正实现了患者居家即可自行完成心理健康治疗”。论文首页截图经颅直流电刺激（tDCS）是一种非侵入性脑刺激，通过将0.5–2mA的弱电流经头皮电极传递到大脑皮层，由阴极和阳极刺激来改变细胞膜的静息电位，从而调节皮质兴奋性。tDCS的治疗设备通常是一个柔软类似泳帽的设备或者带状设备，阳极放置在大脑左侧背外侧前额叶皮质（DLPFC），阴极则放置在右侧DLPFC。DLPFC脑区与大脑的几个重要神经网络密切相关，包括默认模式网络、前额顶叶网络等，已有证据表明，tDCS通过调节DLPFC皮质兴奋性和这些网络的连接，有助于改善抑郁症患者的症状。参考图[3,4]（并非该论文所使用的仪器）此次由Cynthia H. Y. Fu团队带领完成的这项研究是完全远程的双盲随机对照试验（NCT05202119），他们在2022年-2023年期间完成患者招募，最终有174名符合标准的抑郁症患者被纳入研究。患者平均年龄为37.63岁，女性占比69%。入组时所有患者根据《精神障碍诊断与统计手册》第五版确诊为中度或重度抑郁症，汉密顿抑郁量表（HDRS）得分至少为16分，平均得分为19.07分。患者在研究开始前的至少6周内接受过不同程度的抗抑郁药物治疗或心理治疗。患者随机分配入组，分别接受tDCS治疗和假治疗。疗程为期10周，前3周时治疗频率为5次/周，之后7周时治疗频率为3次/周，每次治疗时长30分钟。作为对照组，接受假治疗的患者佩戴耳机样的设备，在每次治疗开始时仅接受短暂的电流脉冲，可以模拟tDCS的感受。治疗期间患者不知晓自己的治疗方式。在10周治疗结束时，tDCS治疗组的抑郁症状显著改善，HDRS评分平均减少9.41分，相比之下，假治疗组的得分减少7.14分，tDCS更胜一筹（P=0.012）。另外根据HDRS评分，tDCS治疗组的临床应答率和临床缓解率为58.3%和44.9%，均显著高于假治疗组的37.8%（P=0.017）和21.8%（P=0.004），进一步体现出tDCS具有明显有效的抑郁症治疗效果。抑郁严重程度评级随时间的变化按照Montgomery-Asberg抑郁量表（MADRS）进行评分时，tDCS治疗组的抑郁症状平均改善11.31分，假治疗组为7.74分（P=0.006）。两组的临床应答率分别为64.2%和32.3%（P<0.001），临床缓解率分别为57.5%和29.4%（P=0.002）。在探索性分析中，tDCS治疗组和假治疗组在焦虑症状、认知功能方面没有显著差异。但是，tDCS治疗组的杨氏躁狂状态评定量表（YMRS）得分显著低于假治疗组，分别为1.27和1.84（P=0.03），表明tDCS对轻度躁症症状的缓解具有一定作用。安全性评估结果显示，tDCS治疗组的皮肤红肿、皮肤刺激和注意力问题的发生率高于假治疗组，两组在头痛、颈部疼痛、头皮疼痛、瘙痒、灼烧感、嗜睡或情绪急性变化方面没有显著差异，没有发生治疗相关严重不良反应。一些不良事件的发生情况此次试验采用完全远程的形式，患者在家中自行使用设备，每次治疗时仅需通过视频会议与研究团队联系，确保正确操作。试验结果积极，表明tDCS在家庭环境下用于抑郁症治疗能够显著改善患者的抑郁症状，提高临床反应率和缓解率。在此之前，不乏有研究探讨tDCS用于患者居家自行治疗的可行性，有得出结论为tDCS无法改善患者症状。但是这些临床试验的治疗时长较短，治疗周期均为六周。对于试验结论的差异，德国慕尼黑大学的精神病学家Frank Padberg表示这不是件坏事[2]，而是提醒我们下一步该去探索tDCS治疗的适用人群。美国神经心理学家Shawn McClintock也展望[2]，未来还可以通过脑成像和电信号记录来实时观察 tDCS 治疗期间神经回路的实际变化。随着tDCS在居家治疗中的可行性不断得到证实，它距离成为抑郁症的一线治疗方案也越来越近。未来，我们仍需对其安全性进行持续监控，以确保长期应用的有效性和安全性。参考文献：[1]Woodham, R.D., Selvaraj, S., Lajmi, N. et al. Home-based transcranial direct current stimulation treatment for major depressive disorder: a fully remote phase 2 randomized sham-controlled trial. Nat Med (2024). https://doi.org/10.1038/s41591-024-03305-y[2]https://www.nature.com/articles/d41586-024-03446-7[3]Thair H, Holloway AL, Newport R, Smith AD. Transcranial Direct Current Stimulation (tDCS): A Beginner's Guide for Design and Implementation. Front Neurosci. 2017 Nov 22;11:641. doi: 10.3389/fnins.2017.00641. PMID: 29213226; PMCID: PMC5702643.[4]Rosa, M. A., & Lisanby, S. H. (2012). Somatic treatments for mood disorders. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 37(1), 102–116. https://doi.org/10.1038/npp.2011.225本文作者丨张艾迪

临床2期临床终止临床研究临床结果